Plaque Psoriasis Clinical Trial
Official title:
A Phase 3 Randomized, Double-Blind, Placebo- and Active-Controlled Study of the Efficacy and Safety of Daily CF101 Administered Orally in Patients With Moderate-to-Severe Plaque Psoriasis
Verified date | June 2022 |
Source | Can-Fite BioPharma |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This trial will test the hypothesis that the administration of CF101, a novel anti-inflammatory agent, to patients with moderate to severe plaque psoriasis will relieve signs and symptoms of the disease. CF101 effect will be in comparison to apremilast in this study population
Status | Completed |
Enrollment | 528 |
Est. completion date | April 27, 2022 |
Est. primary completion date | January 6, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 80 Years |
Eligibility | Inclusion Criteria: 1. Male or female, 18 to 80 years of age, inclusive; 2. Diagnosis of moderate-to-severe chronic plaque-type psoriasis with BSA involvement =10%, as judged by the Investigator; 3. PASI score =12 (Appendix 3) 4. Static PGA =3 (Appendix 2) 5. Candidate for systemic treatment or phototherapy for psoriasis; 6. Duration of psoriasis of at least 6 months; 7. Elevated whole blood A3AR expression level, defined as = 1.5-fold over a predetermined normal population standard at Screening; 8. Females of child-bearing potential must have a negative serum pregnancy test at screening; 9. Females of child-bearing potential must be willing to use 2 methods of contraception deemed adequate by the Investigator (for example, oral contraceptive pills plus a barrier method) to be eligible for, and continue participation in, the study; 10. Ability to complete the study in compliance with the protocol; and 11. Ability to understand and provide written informed consent. Exclusion Criteria: 1. Psoriasis limited to erythrodermic, guttate, palmar, plantar, or generalized pustular psoriasis in the absence of plaque psoriasis; 2. Prior treatment with apremilast within 4 weeks prior to the Baseline visit, or contraindication to apremilast; 3. Treatment with systemic retinoids, corticosteroids, tofacitinib, or immunosuppressive agents (e.g., methotrexate, cyclosporine) within 4 weeks of the Baseline visit; 4. Treatment with a biological agent (etanercept, adalimumab, efalizumab, infliximab, ustekinumab, alefacept, secukinumab, or others, including investigational agents) within a period of time equal to 5 times its circulating half-life, or 30 days, whichever is longer, prior to the Baseline visit; 5. Treatment with high potency topical dermatological corticosteroids (Class I-III in US, Class III-IV in Europe), Vitamin D analogs, keratolytics, or coal tar (other than on the scalp, palms, groin, and/or soles) within 2 weeks of the Baseline visit; 6. Ultraviolet or Dead Sea therapy within 4 weeks of the Baseline visit, or anticipated need for either of these therapies during the study period; 7. Treatment with lithium, hydroxychloroquine or chloroquine within 2 weeks of the Baseline visit, or anticipated need for such drugs during the study period, unless dose has been stable for 3 months prior to the Screening visit and will remain stable throughout the trial; 8. Serum creatinine level greater than 1.5 times the laboratory's upper limit of normal at Screening; 9. Liver aminotransferase levels greater than 1.5 times the laboratory's upper limit of normal at Screening; 10. Electrocardiogram (ECG) at Screening shows abnormalities which, in the judgment of the Investigator, are clinically significant and could, in the judgment of the Principal Investigator, compromise subject safety; 11. Active gastrointestinal disease which could interfere with the absorption of oral medication; 12. Pregnancy, planned pregnancy, lactation, or inadequate contraception as judged by the Investigator; 13. Active drug or alcohol dependence; 14. History of depression or suicidal ideation within the past year; 15. Concomitant use of strong cytochrome P450 inducers, eg, rifampin, phenobarbital, phenytoin, carbamazepine; 16. Previous participation in a CF101 clinical trial; 17. Significant acute or chronic medical or psychiatric illness that, in the judgment of the Investigator, could compromise subject safety, limit the subject's ability to complete the study, and/or compromise the objectives of the study; 18. Participation in another investigational drug or vaccine trial concurrently or within 30 days prior to the Screening visit. |
Country | Name | City | State |
---|---|---|---|
Bosnia and Herzegovina | Clinical Centre of Republika Srpska | Banja Luka | |
Bosnia and Herzegovina | University Clinical Centre Mostar | Mostar | |
Bosnia and Herzegovina | Clinical Centre of Sarajevo University | Sarajevo | |
Bulgaria | "Multiprofile Hospital for Active Treatment - Pazardzhik" | Pazardzhik | |
Bulgaria | "MHAT"Rahila Angelova"AD, Department of Skin and Venereal Diseases | Pernik | |
Bulgaria | "University Multiprofile Hospital for Active Treatment - D-r Georgi Stranski" - EAD, Pleven, Clinic of Skin and Venereal Diseases | Pleven | |
Bulgaria | "Diagnostic-Consultative Aleksandrovska" EOOD | Sofia | |
Bulgaria | "Diagnostic-Consultative Centre XX - Sofia" EOOD | Sofia | |
Bulgaria | Ambulatory for Specialized Medical Help - Group Practice Dermatology - Clinic EuroDerma" OOD | Sofia | |
Canada | K. Papp Clinical Research | Waterloo | |
Croatia | Clinical Hospital Center Rijeka | Rijeka | |
Croatia | Sestre milosrdnice University Hospital Center | Zagreb | |
Israel | Rambam Medical Center | Haifa | |
Moldova, Republic of | Institutul de Cardiologie | Chisinau | |
Moldova, Republic of | Spitalul Clinic Municipal Nr. 3 "Sfanta Treime" | Chisinau | |
Moldova, Republic of | Spitalul Clinic Republican | Chisinau | |
Poland | Centrum Uslug Medycznych MaxMed | Bochnia | |
Poland | Gdanskim Centrum Zdrowia | Gdansk | |
Poland | All-MED Centrum Medyczne | Lódz | |
Poland | Miejski Szpital Zespolony Klinika Dermatologii Chorób Przenoszonych Droga Plciowa i Immunologii klinicznej | Olsztyn | |
Poland | Lubelskie Centrum Diagnostyczne | Swidnik | |
Poland | ETG Zamosc, ul. Szczebrzeska 11i | Zamosc | |
Romania | Centrul Medical de Diagnostic si Tratament Ambulator Neomed SRL | Brasov | |
Romania | SC PELICAN Impex SRL | Oradea | |
Romania | Spitalul Clinic Jude?ean de Urgen?a Sibiu | Sibiu | |
Serbia | Clinical Centre of Serbia | Belgrade | |
Serbia | Clinical Centre Nis | Niš | |
Serbia | Military Hospital Nis | Niš | |
Serbia | General Hospital Sremska Mitrovica | Sremska Mitrovica | |
Serbia | General Hospital Zajecar | Zajecar |
Lead Sponsor | Collaborator |
---|---|
Can-Fite BioPharma |
Bosnia and Herzegovina, Bulgaria, Canada, Croatia, Israel, Moldova, Republic of, Poland, Romania, Serbia,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Psoriasis Area and Severity Index (PASI) score response of =75% (PASI 75) at Week 16 | Evaluate the efficacy of oral CF101 2 mg or 3 mg twice daily (BID) in patients with moderate-to-severe plaque psoriasis, compared with placebo, as determined by the proportion of subjects who achieve a Psoriasis Area and Severity Index (PASI) score response of =75% (PASI 75) at Week 16 (superiority) | 16 weeks | |
Primary | Adverse event profile in this patient popluation | Nature, incidence and severity of treatment-emergent adverse events | 16 weeks | |
Secondary | Psoriasis Area and Severity Index (PASI) score response of =50% (PASI 50) at Week 16 | Evaluate the efficacy of oral piclidenoson 2 mg or 3 mg BID, compared with placebo, as determined by the proportion of subjects who achieve PASI 50 at Week 16 (superiority); | 16 weeks | |
Secondary | Physician Global Assessment (PGA) | Evaluate the efficacy of oral piclidenoson 2 mg or 3 mg BID, compared with placebo, as determined by the proportion of subjects who achieve PGA score of 0 or 1 at Week 16; | 16 weeks | |
Secondary | Psoriasis Disability Index (PDI) | Evaluate the efficacy of oral piclidenoson 2 mg or 3 mg BID, compared with placebo, as determined by the proportion of subjects who achieve improvement on the PDI at Week 16; | 16 weeks | |
Secondary | CF101 PASI 75 compare to apremilast | Evaluate the efficacy of oral piclidenoson 2 mg or 3 mg BID, compared with apremilast, as determined by the proportion of subjects who achieve PASI 75 at Weeks 16 and 32; | weeks 16-32 | |
Secondary | CF101 PGA score compare to apremilast | Evaluate the efficacy of oral piclidenoson 2 mg or 3 mg BID, compared with apremilast, as determined by the proportion of subjects who achieve PGA score of 0 or 1, at Weeks 16 and 32; | weeks 16-32 | |
Secondary | CF101 PASI 50 compare to apremilast | Evaluate the efficacy of oral piclidenoson 2 mg or 3 mg BID, compared with apremilast, as determined by the proportion of subjects who achieve PASI 50 at Weeks 16 and 32; | weeks 16-32 | |
Secondary | CF101 PDI improvement compare to apremilast | Evaluate the efficacy of oral piclidenoson 2 mg or 3 mg BID, compared with apremilast, as determined by the proportion of subjects who achieve an improvement in PDI at Weeks 16 and 32; | weeks 16-32 | |
Secondary | Apremilast PASI 75 compare to placebo | Establish assay sensitivity within this trial by comparing the efficacy of apremilast 30 mg BID with that of placebo tablets BID, as determined by the proportion of subjects who achieve PASI 75, PGA score of 0 or 1, PASI 50, and improvement in PDI at Week 16 (superiority); | weeks 16-32 | |
Secondary | Apremilast PGA compare to placebo | Establish assay sensitivity within this trial by comparing the efficacy of apremilast 30 mg BID with that of placebo tablets BID, as determined by the proportion of subjects who achieve PGA score of 0 or 1 at Week 16; | weeks 16-32 | |
Secondary | Apremilast PASI 50 compare to placebo | Establish assay sensitivity within this trial by comparing the efficacy of apremilast 30 mg BID with that of placebo tablets BID, as determined by the proportion of subjects who achieve PASI 50 at Week 16; | weeks 16-32 | |
Secondary | Apremilast PDI compare to placebo | Establish assay sensitivity within this trial by comparing the efficacy of apremilast 30 mg BID with that of placebo tablets BID, as determined by the proportion of subjects who achieve improvement in PDI at Week 16; | 16 weeks | |
Secondary | Adverse event profile of piclidenoson through the Extension Period of up to 48 weeks of treatment | Nature, incidence, and severity of treatment-emergent adverse events | 48 weeks | |
Secondary | Efficacy of piclidenoson, as determined by changes in PASI score, through the Extension Period of up to 48 weeks of treatment | The proportion of subjects who achieve a Psoriasis Area and Severity Index (PASI) score response of =75% (PASI 75) at Week 48 | 48 weeks | |
Secondary | Determine pharmacokinetics (PK) of piclidenoson under the circumstances of this trial using sparse sampling | Serum concentration of piclidenoson | 48 weeks | |
Secondary | Evaluate the relationship between pre-treatment whole blood A3 adenosine receptor (A3AR) expression levels and response to piclidenoson treatment. | Explore the relationship between white blood cell (WBC) adenosine A3 receptor (A3AR) expression and treatment response, by taking WBC sample at baseline | 16 weeks |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT01194219 -
Study to Evaluate Safety and Effectiveness of Oral Apremilast (CC-10004) in Patients With Moderate to Severe Plaque Psoriasis
|
Phase 3 | |
Recruiting |
NCT06030076 -
A Study to Assess the Effects of Switching From a Biologic Treatment to Tildrakizumab Using Patient-reported Outcomes in Adult Participants With Moderate to Severe Plaque Psoriasis
|
||
Completed |
NCT04263610 -
Efficacy and Safety of Tildrakizumab in Participants With Moderate-to-Severe Chronic Plaque Psoriasis Who Are Non-Responders to Dimethyl Fumarate Therapy
|
Phase 4 | |
Completed |
NCT02601469 -
Study to Assess the Potential for Adrenal Suppression Following Treatment With DSXS in Patients With Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT05600036 -
A Study to Evaluate the Efficacy and Safety of ESK-001 in Patients With Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT05375955 -
A Study to Learn About The Study Medicine (PF-07038124) In Patients With Mild To Moderate Atopic Dermatitis Or Mild To Severe Plaque Psoriasis.
|
Phase 2 | |
Completed |
NCT03614078 -
A Study of PRCL-02 in Moderate to Severe Chronic Plaque Psoriasis
|
Phase 2 | |
Not yet recruiting |
NCT05036889 -
A 16-week Randomized Evaluation of the Impact of Mind.Px Application on Response to Biologic Treatment in Patients Suffering From Plaque Psoriasis Through Clinical Utility and Health Outcomes.
|
N/A | |
Completed |
NCT04603027 -
A Phase 2 Study Investigating the Effect of EDP1815 in the Treatment of Mild to Moderate Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT03638258 -
The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT02881346 -
Efficacy and Tolerability of Enstilar® in Daily Practice
|
||
Recruiting |
NCT02611349 -
Study to Evaluate the Long-Term Safety of IDP-118 Lotion in the Treatment of Plaque Psoriasis
|
Phase 3 | |
Completed |
NCT02251678 -
Evaluate the Effect of Elimune Capsules
|
Phase 1 | |
Completed |
NCT01987843 -
Dose-finding Study of MT-1303 in Subjects With Moderate to Severe Chronic Plaque Psoriasis
|
Phase 2 | |
Terminated |
NCT01708629 -
Efficacy and Safety of Brodalumab Compared With Placebo and Ustekinumab in Moderate to Severe Plaque Psoriasis Subjects
|
Phase 3 | |
Withdrawn |
NCT00747032 -
To Demonstrate the Superior Efficacy of NYC 0462 Ointment Over That of the Placebo in the Treatment of Plaque Psoriasis
|
Phase 3 | |
Completed |
NCT01230138 -
Pivotal Efficacy and Safety Registration Trial of FP187 in Moderate to Severe Plaque Psoriasis
|
Phase 2 | |
Completed |
NCT00581100 -
Effects of Etanercept on Nail Psoriasis and Plaque Psoriasis
|
Phase 4 | |
Suspended |
NCT01228656 -
Effectiveness of Association Mometasone Furoate 0.1% and Salicylic Acid 5% Compared With Mometasone Furoate
|
Phase 2 | |
Completed |
NCT00540618 -
A Phase II Study of MEDI-507, Administered by Injection to Adults With Psoriasis
|
Phase 2 |